CC-1 / University Hospital Tuebingen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Checkpoint inhibition, Checkpoint block:  Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) -  Jul 27, 2023   
    P1/2,  N=3, Terminated, 
    Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024 N=86 --> 3 | Trial completion date: Sep 2025 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; premature termination of the trial due to bad recruitment
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Enrollment open:  ProSperACC-1: Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (clinicaltrials.gov) -  Jan 12, 2023   
    P1,  N=56, Recruiting, 
    N=86 --> 3 | Trial completion date: Sep 2025 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; premature termination of the trial due to bad recruitment Not yet recruiting --> Recruiting
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Enrollment open, Checkpoint inhibition, Checkpoint block:  Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) -  Feb 17, 2022   
    P1/2,  N=86, Recruiting, 
    Trial completion date: Sep 2022 --> Aug 2023 | Trial primary completion date: Mar 2022 --> Mar 2023 Not yet recruiting --> Recruiting
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block:  Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) -  Dec 14, 2021   
    P1/2,  N=86, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: May 2023 --> Mar 2025
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition, Checkpoint block:  Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) -  Mar 9, 2021   
    P1/2,  N=86, Not yet recruiting, 
    Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: May 2023 --> Mar 2025 Trial completion date: May 2024 --> Jan 2025 | Initiation date: Sep 2020 --> May 2021 | Trial primary completion date: Sep 2023 --> May 2023
  • ||||||||||  CC-1 / University Hospital Tuebingen
    Trial primary completion date:  the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov) -  Apr 24, 2020   
    P1,  N=86, Recruiting, 
    Trial completion date: May 2024 --> Jan 2025 | Initiation date: Sep 2020 --> May 2021 | Trial primary completion date: Sep 2023 --> May 2023 Trial primary completion date: Mar 2020 --> Mar 2022